Journal
/
/
Patient-Derived Tumor Explants As a “Live” Preclinical Platform for Predicting Drug Resistance in Patients
JoVE Journal
Cancer Research
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Cancer Research
Patient-Derived Tumor Explants As a “Live” Preclinical Platform for Predicting Drug Resistance in Patients
DOI:

07:42 min

February 07, 2021

, , , , , , , , , , ,

Chapters

  • 00:04Introduction
  • 00:45Explant Preparation and Drug Treatment
  • 02:12Histological Processing
  • 03:09Training Analysis
  • 06:04Results: Representative Patient-Derived Explant Responses to Tumor Drugs of Interest
  • 07:02Conclusion

Summary

Automatic Translation

This paper describes methods for the generation, drug treatment, and analysis of patient-derived explants for assessing tumor drug responses in a live, patient-relevant, preclinical model system.

Related Videos

Read Article